An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs SAR 422459 (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Sponsors Oxford BioMedica; Sanofi
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2019 Planned End Date changed from 1 Feb 2035 to 1 Jun 2034.
- 10 Apr 2019 Planned primary completion date changed from 1 Feb 2035 to 1 Jun 2034.